903597-10-4

Basic information

• Product Name: N’-(2-cyano-4-iodophenyl)-N,N-dimethyl formamidine
• Synonyms: N’-(2-cyano-4-iodophenyl)-N,N-dimethyl formamidine
• CAS NO: 903597-10-4
• Molecular Weight: 299.114
• Mol File: 903597-10-4.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: N’-(2-cyano-4-iodophenyl)-N,N-dimethyl formamidine(CAS DataBase Reference)
• NIST Chemistry Reference: N’-(2-cyano-4-iodophenyl)-N,N-dimethyl formamidine(903597-10-4)
• EPA Substance Registry System: N’-(2-cyano-4-iodophenyl)-N,N-dimethyl formamidine(903597-10-4)

Safety Data

• Hazardous Substances Data: 903597-10-4(Hazardous Substances Data)

Upstream product

• 21511-55-7 (methoxymethylidene)dimethylammonium methyl sulfate 
• 132131-24-9 5-iodoanthranilonitrile 
• 1885-29-6 anthranilic acid nitrile 
• 4637-24-5 N,N-dimethyl-formamide dimethyl acetal 
• 68-12-2 N,N-dimethyl-formamide 

Downstream Products

• 231278-20-9 N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-iodoquinazolin-4-amine 
• 231277-92-2 lapatanib 
• 231278-84-5 5-(4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)quinazolin-6-yl)furan-2-carbaldehyde 
• 388082-78-8 lapatinib ditosylate 
• 1227853-06-6 N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-(5-((2-(methylsulfonyl)ethylimino)methyl)furan-2-yl)quinazolin-4-amine 
• 1024611-38-8 N-(2-ethoxy-4-morpholinophenyl)-6-(thiazol-2-yl)quinazolin-4-amine 
• 1024611-37-7 N-(2-methoxy-4-morpholinophenyl)-6-(thiazol-2-yl)quinazolin-4-amine 
• 1024611-36-6 (2-methyl-4-morpholin-4-yl-phenyl)-(6-thiazol-2-yl-quinazolin-4-yl)-amine 
• 1024611-39-9 N'-(2-cyano-4-thiazol-2-yl-phenyl)-N,N-dimethyl-formamidine 
• 944279-13-4 N'-[2-cyano-4-(2,3-dihydro-benzo[1,4]dioxin-6-yl)-phenyl]-N,N-dimethyl-formamidine 
• 944279-15-6 N'-(2-cyano-4-thiophen-2-yl-phenyl)-N,N-dimethyl-formamidine 
• 934426-23-0 3-cyano-4-(dimethylamino-methyleneamino)-phenylboronic acid 
• 578737-95-8 N-(3-chloro-4-fluorophenyl)-6-iodo-4-quinazolinamine 
• 1421356-86-6 N-(3-chloro-4-fluorophenyl)-6-(5-formyl-2-furyl)-4-quinazolinamine 

Relevant articles and documents

Novel 4-arylaminoquinazolines bearing N,N-diethyl(aminoethyl)amino moiety with antitumour activity as EGFRwt-TK inhibitor

Herein, four novel 4-arylaminoquinazoline derivatives with N,N-diethyl(aminoethyl)amino moiety were designed, synthesised and evaluated on biological activities in vitro. All synthesised compounds have inhibitory effects against tumour cells (SW480, A549, A431 and NCI-H1975). In particular, 4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)-6-(5-((N,N-diethyl(aminoethyl))aminomethyl)furan-2-yl)quinazoline (6a) and 6-(5-((N,N-diethylethyl)aminomethyl)furan-2-yl)-4-(4-(E)-(propen-1-yl)phenylamino)quinazoline (6d) were potent antitumour agents which showed high antiproliferative activities against tumour cells in vitro. Moreover, compound 6a could induce late apoptosis of A549 cells at high concentrations and arrest cell cycle of A549 cells in the G0/G1 phase at tested concentrations. Also, compound 6a could inhibit the activity of wild type epidermal growth factor receptor tyrosine kinase (EGFRwt-TK) with IC50 value of 15.60 nM. Molecular docking showed that compound 6a formed three hydrogen bonds with EGFRwt-TK, while lapatinib formed only two hydrogen bonds with the receptor protein. It is believed that this work would be giving a reference for developing anti-cancer drugs targeted EGFR-TK.

Quinazoline-1-deoxynojirimycin hybrids as high active dual inhibitors of EGFR and α-glucosidase

A series of novel quinazoline-1-deoxynojirimycin hybrids were designed, synthesized and evaluated for their inhibitory activities against two drug target enzymes, epidermal growth factor receptor (EGFR) tyrosine kinase and α-glucosidase. Some synthesized compounds exhibited significantly inhibitory activities against the tested enzymes. Comparing with reference compounds gefitinib and lapatinib, compounds 7d, 8d, 9b and 9d showed higher inhibitory activities against EGFR (IC50: 1.79–10.71 nM). Meanwhile the inhibitory activities of 7d, 8d and 9c against α-glucosidase (IC50 = 0.14, 0.09 and 0.25 μM, respectively) were obvious higher than that of miglitol (IC50 = 2.43 μM), a clinical using α-glucosidase inhibitor. Interestingly, compound 9d as a dual inhibitor showed high inhibitory activity to EGFRwt tyrosine kinase (IC50 = 1.79 nM), also to α-glucosidase (IC50 = 0.39 μM). The work could be very useful starting point for developing a new series of enzyme inhibitors targeting EGFR and/or α-glucosidase.

A NEW PROCESS FOR THE PREPARATION OF LAPATINIB AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS

The present invention relates to an improved and new process for the preparation of high purity crystalline base of Lapatinib of formula (1) having chemical name N-{3-chloro-4-[(3-fluorobenzyloxy]phenyl}-6-[5-({[2-(methanesulfonyl) ethyl]amino}methyl]-2-furyl]-4-quin -azolinamine and its pharmaceutically acceptable salts.